Farnesyltransferase Inhibitors

Seminars in Oncology

Volumn 31, Issue 1 SUPPL. 1, 2004, Pages 28-39

  Sebti, Said M ^b   Adjei, Alex A ^a  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,4,9,9A HEXAHYDRO 2 [2 (2 METHOXYPHENYL) 1 OXO 2 PROPENYL] 9 (4 METHYLPHENYL) 4,9 ETHANO 3AH BENZ[F]ISOINDOLE 3A CARBOXYLIC ACID; BMS 184878; BMS 193269; BZA2B; BZA5B; CYTOTOXIC AGENT; FTI 2148; FTI 2153; GERANYLGERANYLTRANSFERASE 1; GERANYLTRANSFERASE; L 745631; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE 1; N (8 AMINO 2 BENZYL 5 ISOPROPYL 9 MERCAPTO 3,6 NONADIENOYL)METHIONINE; N (8 AMINO 2 BENZYL 5 ISOPROPYL 9 MERCAPTO 3,6 NONADIENOYL)METHIONINE METHYL ESTER; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE METHYL ESTER; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE B; PROTEIN P16; PROTEIN P53; RAF PROTEIN; RAS PROTEIN; RHO FACTOR; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG TARGETING; GLIOMA; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MYELODYSPLASTIC SYNDROME; NONHUMAN; ONCOGENE H RAS; ONCOGENE K RAS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW;

EID: 1242273875     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.12.012     Document Type: Article

References (81)

1. Barbacid M: Ras genes. Ann Rev Biochem 56:779-827, 1987
2. Sebti SM, Hamilton AD: Anticancer activity of farnesyltransferase and geranylgeranyltransferase I inhibitors: Prospects for drug development. Exp Opin Invest Drugs 6:1711-1714, 1997
3. Sebti SM, Hamilton AD: Farnesyltransferase and geranylgeranyltransferase I inhibitors as novel agents for cancer and cardiovascular diseases, in Sebti M, Hamilton AD (eds): Farnesyltransferase Inhibitors in Cancer Therapy. Totowa, NJ, Humana Press, 2000, pp 197-220
4. Cox AD, Der CJ: Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras? Biochim Biophys Acta 1333:F51-F71, 1997
5. Gibbs JB, Oliff A: The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol 37:143-166, 1997
6. Sebti SM, Hamilton AD: Inhibition of Ras prenylation: A novel approach to cancer chemotherapy. Pharmacol Ther 74:103-114, 1997
7. Casey PJ, Seabra MC: Protein prenyltransferases. J Biol Chem 271:5289-5296, 1996
8. Pompliano DL, Rands E, Schaber MD, et al: Steady-state kinetic mechanism of Ras farnesyl: protein transferase. Biochem 31:3800-3807, 1992
9. Tschantz WR, Furfine ES, Casey PJ: Substrate binding is required for release of product from mammalian protein farnesyltransferase. J Biol Chem 272:9989-9993, 1997
10. Furfine ES, Leban JJ, Landavazo A, et al: Protein farnesyltransferase: Kinetics of farnesyl pyrophosphate binding and product release. Biochem 34:6857-6862, 1995
11. Long SB, Beese LS: Structures of protein farnesyltransferasein, in Sebti SM, Hamilton AD (eds): Structures of Protein Farnesyltransferase. Totowa JN, 2000, Humana Press, 2000, pp 37-48
12. Sun J, Blaskovich MA, Knowles D, et al: Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res 59:4919-4926, 1999
13. Reiss Y, Goldstein JL, Seabra MC, et al: Inhibition of purified p21ras farnesyl: protein transferase by Cys-AAX tetrapeptides. Cell 62:81-88, 1990
14. Lerner EC, Qian Y, Blaskovich MA, et al: Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem 270:26802-26806, 1995
15. James GL, Goldstein JL, Brown MS: Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem 270:6221-6226, 1995
16. Whyte DB, Kirschmeier P, Hockenberry TN, et al: K-and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272:14459-14464, 1997
17. Rowell CA, Kowalczyk JJ, Lewis MD, et al: Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J Biol Chem 272:14093-14097, 1997
18. Lerner EC, Zhang TT, Knowles DB, et al: Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene 15:1283-1288, 1997
19. Sun J, Qian Y, Hamilton AD, et al: Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 16:1467-1473, 1998
20. Sun J, Qian Y, Hamilton AD, et al: Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res 55:4243-4247, 1995
21. Bredel M, Pollack IF, Freund JM, et al: Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth. Neurosurgery 43:124-131; discussion 131-132, 1998
22. Pollack IF, Bredel M, Erff M, et al: Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II-Preclinical studies in a nude mouse model. Neurosurgery 45:1208-1214, 1999
23. Gibbs JB, Graham SL, Hartman GD, et al: Antitumor efficacy of a farnesyltransferase inhibitor in transgenic mice, in Sebti SM, Hamilton AD (eds): Farnesyltransferase Inhibitors in Cancer Therapy. Totowa, NJ, Humana Press, 2000, pp 65-70
24. Omer CA, Chen Z, Diehl RE, et al: Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl: protein transferase inhibitor. Cancer Res 60:2680-2688, 2000
25. Lantry LE, Zhang Z, Yao R, et al: Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis 21:113-116, 2000
26. Vogt A, Qian Y, Hamilton AD, et al: The geranylgeranyltransferase I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21WAF1/CIP1/SDII in a-p53 independent manner. J Biol Chem 272:27224-27229, 1997
27. Sepp-Lorenzino L, Rosen N: A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells. J Biol Chem 273:20243-20251, 1998
28. Ashar HR, et al: Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem 275:30451-30457, 2000
29. Hussein D, Taylor SS: Farnesylation of Cenp-F is required for G2/M progression and degradation after mitosis. J Cell Sci 115:3403-3414, 2002
30. Crespo NC, Ohkanda J, Yen TJ, et al: The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J Biol Chem 276:16161-16167, 2001
31. Crespo NC, Delarue F, Ohkanda J, et al: The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status. Cell Death Differ 9:702-709, 2002
32. Lee J, Miyano T, Dai Y, et al: Specific regulation of CENP-E and kinetochores during meiosis I/meiosis II transition in pig oocytes. Mol Reprod Dev 56:51-62, 2000
33. Lebowitz PF, Sakamuro D, Prendergast GC: Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Res 57:708-713, 1997
34. Suzuki N, Urano J, Tamanoi F: Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc Natl Acad Sci U S A 95:15356-15361, 1998
35. Jiang K, Coppola D, Crespo NC, et al: The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol 20:139-148, 2000
36. Du W, Liu A, Prendergast GC: Activation of the PI3′K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors. Cancer Res 59:4208-4212, 1999
37. Zhang FL, Casey PJ: Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 65:241-269, 1996
38. Sepp-Lorenzino L, Ma Z, Rands E, et al: A peptidomimetic inhibitor of farnesyl: protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 55:5302-5309, 1995
39. Voice JK, Klemke RL, Le A, et al: Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility. J Biol Chem 274:17164-17170, 1999
40. Yan J, Roy S, Apolloni A, et al: Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J Biol Chem 273:24052-24056, 1998
41. Nagasu T, Yoshimatsu K, Rowell C, et al: Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res 55:5310-5314, 1995
42. Lebowitz PF, Casey PJ, Prendergast GC, et al: Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J Biol Chem 272:15591-15594, 1997
43. Du W, Prendergast GC: Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors. Cancer Res 59:5492-5496, 1999
44. Liu A, Du W, Liu JP, et al: RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Mol Cell Biol 20:6105-6113, 2000
45. Chen Z, Sun J, Pradines A, et al: Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. J Biol Chem 275:17974-17978, 2000
46. Zohn IM, Campbell SL, Khosravi-Far R, et al: Rho family proteins and Ras transformation: The RHOad less traveled gets congested. Oncogene 17:1415-1438, 1998
47. Adnane J, Muro-Cacho C, Mathews L, et al: Suppression of Rho B expression in invasive carcinoma from head and neck cancer patients. Clin Cancer Res 8:2225-2232, 2002
48. Haluska P, Dy GK, Adjei AA: Farnesyltransferase inhibitors as anticancer agents. Eur J Oncol 38:1685-1700, 2002
49. Karp JE, Lancet JE, Kaufmann SH, et al: Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase I clinical-laboratory correlative trial. Blood 97:3361-3369, 2001
50. Reichert A, Heisterkamp N, Daley GQ, et al: Treatment of Bcr/ Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood 97:1399-1403, 2001
51. Harousseau J-L, Stone R, Thomas X, et al: Interim results from a phase II study of R115777 (Zarnestra) in patients with relapsed and refractory acute myelogenous leukemia. Proc Am Soc Clin Oncol 21:265a, 2002 (abstr 1056)
52. Keating A: Chronic myeloid leukemia: Current therapies and the potential role of farnesyltransferase inhibitors. Semin Hematol 39:11-17, 2002 (suppl 2)
53. Kurzrock R, Sebti SM, Kantarjian HM, et al: Phase I study of a farnesyl transferase inhibitor, R115777, in patients with myelodysplastic syndrome. Blood 98:623a, 2001 (abstr 2609)
54. Kurzrock R, Cortes J, Ryback ME, et al: Phase II study of R115777, a farnesyltransferase inhibitor, in myelodysplastic syndrome. Blood 98:848, 2001 (abstr 3520)
55. Gotlib J, Dugan K, Katamneni U, et al: Phase I/II study of farnesyltransferase inhibitor R115777 (Zarnestra) in patients with myeloproliferative disorders (MPDs): Preliminary results. Proc Am Soc Clin Oncol 21:4a, 2002 (abstr 14)
56. Alsina M, Overton R, Belle N, et al: Farnesyltransferase inhibitor FTI-R115777 is well tolerated, induces stabilization of disease and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Proc Am Assoc Cancer Res 43:1000, 2002 (abstr 4960)
57. Kurzrock R, Wilson EF, Sebti SM: Clinical activity and inhibition of protein farnesylation of FTI-R115777 treated patients with myelodysplastic syndrome (MDS). Proc Am Assoc Cancer Res 43:1000, 2002 (abstr 4959)
58. Winquist E, Moore MJ, Chi K, et al: NCIC CTG IND.128: A phase II study of a farnesyl transferase inhibitor (SCH 66336) in patients with unresectable or metastatic transitional cell carcinoma of the urothelial tract failing prior chemotherapy. Proc Am Soc Clin Oncol 20:197a, 2001 (abstr 785)
59. Haas N, Peereboom D, Ranganathan S, et al: Phase II trial of R115777, an inhibitor of farnesyltransferase, in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 21:181a, 2002 (abstr 721)
60. Sharma S, Kemeny N, Kelsen DP, et al: A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann Oncol 13:1067-1071, 2002
61. Cunningham D, de Gramont A, Scheithauer W, et al: Randomized double-blind placebo-controlled trial of the farnesyltransferase inhibitor R115777 (Zarnestra) in advanced refractory colorectal cancer. Proc Am Soc Clin Oncol 21:126a, 2002 (abstr 502)
62. Macdonald JS, Chansky K, Whitehead R, et al: A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer. A Southwest Oncology Group (SWOG) study. Proc Am Soc Clin Oncol 21:138a, 2002 (abstr 548)
63. Cohen SJ, Ho L, Ranganathan S, et al: Phase II and pharmacodynamic trial of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 21:137a, 2002 (abstr 545)
64. Van Cutsem E, Karasek P, Oettle H, et al: Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC). Proc Am Soc Clin Oncol 21:130a, 2002 (abstr 517)
65. Johnston SRD, Hickish T, Houston S, et al: Efficacy and tolerability of two dosing regimens of R115777 (Zarnestra), a farnesyl protein transferase inhibitor, in patients with advanced breast cancer. Proc Am Soc Clin Oncol 21:35a, 2002 (abstr 138)
66. Cloughesy TF, Kuhn J, Wen P, et al: Phase II trial of R115777 (Zarnestra) in patients with recurrent glioma not taking enzyme inducing antiepileptic drugs (EIAED): A North American Brain Tumor Consortium (NABTC) report. Proc Am Soc Clin Oncol 21:80a, 2002 (abstr 317)
67. Kuhn JG, Prados M, Robins HI, et al: Phase I trial of R115777 (Zarnestra) in patients with recurrent malignant glioma taking enzyme inducting antiepileptic drugs (EIAED). A North American Brain Tumor Consortium (NABTC) report. Proc Am Soc Clin Oncol 21:86a, 2002 (abstr 342)
68. Crul M, de Klerk GJ, Swart M, et al: Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 20:2726-2735, 2002
69. Piccart-Gebhart MJ, Branle D, de Valeriola M, et al: A phase I, clinical and pharmacokinetic (PK) trial of the farnesyl transferase inhibitor (FTI) R115777 + docetaxel: A promising combination in patients (PTS) with solid tumors. Proc Am Soc Clin Oncol 20:80a, 2001 (abstr 318)
70. Adjei AA, Bruzek LM, Erlichman C, et al: Combination studies with the farnesyltransferase inhibitor R115777 and chemotherapy agents. Eur J Cancer 37:792, 2001 (suppl 6) (abstr)
71. Adjei AA, Mauer A, Marks R, et al: A phase II study of the farnesyltransferase inhibitor R115777 in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 21:290a, 2002 (abstr 1156)
72. Heymach JV, De Porte PM, Devore RF, et al: Phase II study of the farnesyl transferase inhibitor (FTI) R115777 (Zarnestra) in patients with relapsed small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 21:319a, 2002 (abstr 1275)
73. Adjei AA, Erlichman C, Davis JN, et al: A phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity. Cancer Res 60:1871-1877, 2000
74. Khuri FR, Glisson BS, Meyers ML, et al: Phase I study of farnesyl transferase inhibitor (FTI) SCH66336 with paclitaxel in solid tumors: Dose finding, pharmacokinetics, efficacy/safety. Proc Am Soc Clin Oncol 19:205a, 2000 (abstr 799)
75. Kim ES, Kies MS, Fossella FV, et al: A phase I/II study of the farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) with paclitaxel in taxane-refractory/resistant patients with non-small cell lung cancer (NSCLC): Final report. Proc Am Assoc Cancer Res 43:550, 2002 (abstr 2735)
76. Rose WC, Lee FYF, Fairchild CR, et al: Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Res 61:7507-7517, 2001
77. Camacho LH, Soignet SL, Pezzulli S, et al: Dose escalation study of oral farnesyl transferase inhibitor (FTI) BMS-214662 in patients with solid tumors. Proc Am Soc Clin Oncol 20:79a, 2001 (abstr 311)
78. Ryan DP, Eder JP, Supko JG, et al: Phase I clinical trial of the farnesyltransferase (FT) inhibitor BMS-214662 in patients with advanced solid tumors. Proc Am Soc Clin Oncol 19:720, 2000 (abstr 720)
79. Dy GK, Bruzek LM, Croghan GA, et al: A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662 in combination with paclitaxel and carboplatin in patients with advanced cancer. Proc Am Assoc Cancer Res 43:550, 2002 (abstr 2736)
80. Lantry LE, Zhang Z, Crist KA, Wang Y, et al: Chemopreventive efficacy of promising farnesyltransferase inhibitors. Exp Lung Res 26:773-790, 2000
81. Wright JJ, Zerivitz K, Gravell AE, et al: Clinical trials referral resource. Current clinical trials of R115777 (Zarnestra). Oncology (Huntingt) 16:930-931935-937, 2002